Skip to main content
SpringerLink
Log in

Tachykinin NK1 Receptor Antagonists

  • Chapter
Tachykinins

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 164))

Abstract

This chapter is focused on the pharmacology of most relevant tachykinin NK1 receptor-selective compounds, with emphasis on the progress ofknowledge made possible by their use and on the therapeutic perspectives of these drugs. The first peptide antagonists of SP, synthesized about 20 years ago, were hampered by poor selectivity for NK1 receptors and other serious side effects. Since then the number of new compounds, peptidic at first and nonpeptidic later, being endowed with increasing potency and selectivity toward the NK1 receptor, has been growing continuously. A milestone in the field has been the introduction in 1991 of the first nonpeptide compound, CP96345, by Pfizer. CP96345 was instrumental, along with RP 67580 from Rhone-Poulenc, for recognition of the existence of species-related heterogeneity of NK1 receptors. CP96345 has been used in a plenty of preclinical studies aiming at investigating the pathophysiological role of the NK1 receptor, demonstrating the involvement of this receptor in pain perception and inflammation. The following compounds introduced in the field have been deprived of the undesired ion channel-blocking activity accompanying CP96345 and related compounds. By their use, the involvement of the NK1 receptor in emesis and in mediating affective disorders such as depression and anxiety has been proven. Antiemetic and antidepressive activity in humans has been reported first by CP122721 from Pfizer and by L754030 (MK869) from Merck, respectively. In contrast, disappointing results have been obtained with tachykinin NK1 antagonists tested as analgesics in patients affected by osteorathritis, neuropathic pain, dental pain and migraine, for reasons that are still not fully understood. Tachykinin NK1 receptor-selective antagonists are expected to provide therapeutic effects in peripheral inflammatory diseases such as asthma and inflammatory bowel disease. However, the first trials with these compounds in asthmatic patients have been negative.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Amann R, Schuligoi R, Holzer P, Donnerer J (1995) The non-peptide NK1 receptor antagonist SR140333 produces long-lasting inhibition of neurogenic inflammation, but does not influence acute chemo-or thermonociception in rats. Naunyn Schmiedebergs Arch Pharmacol 352: 201–205

    Article  PubMed  CAS  Google Scholar 

  • Aramori I, Morikawa N, Zenkoh J, O’Donnell N, Iwami M, Kojo H, Notsu Y, Okuhara M, Ono S, Nakanishi S (1994) Subtype-and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and humantachykinin receptors. Eur J Pharmacol 269: 277–281

    Article  PubMed  CAS  Google Scholar 

  • Astolfi M, Patacchini R, Maggi M, Manzini S (1997) Improved discriminatory properties between human and murine tachykinin NK1 receptors of MEN 10930: a new potent and competitive antagonist. Neuropeptides 31: 373–379

    Article  PubMed  CAS  Google Scholar 

  • Barr AJ, Watson SP (1993) Non-peptide antagonists CP 96,345 and RP 67,580, distinguish species variants in tachykinin NK-l receptors. Br J Pharmacol 108: 223–227

    Article  PubMed  CAS  Google Scholar 

  • Beattie DT, Beresford IJ, Connor HE, Marshall FH, Hawcock AB, Hagan RM, Bowers J, Birch PJ, Ward P (1995) The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol 1l6: 3149–3157

    Article  Google Scholar 

  • Beaujouan JC, Heuillet E, Petitet F, Saffroy M, Torrens Y, Glowinski J (1993) Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol 108: 793–800

    Article  PubMed  CAS  Google Scholar 

  • Beresford IJ, Birch PJ, Basalt M-C, Rogers H, Fernandez L, Hagan RM (1991a) Effect of the spirolactam NK-l receptor antagonist GR 82334 on neurokinin-1 and electrical stimulation-induced oedema in the rat. Br J Pharmacol 102:360P

    Google Scholar 

  • Beresford IJ, Birch PJ, Hagan RM, Ireland SJ (1991b) Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol 104: 292–293

    Article  PubMed  CAS  Google Scholar 

  • Birch PJ, Harrison SM, Hayes AG, Rogers H, Tyers MB (1992) The non-peptide NK1 receptor antagonist, (+/-)-CP-96,345, produces anti nociceptive and anti-oedema effects in the rat. Br J Pharmacol l05: 508–510

    Google Scholar 

  • Boni P, Maggi CA, Evangelista S (1994) In vivo evidence for the activation of a septidesensitive tachykinin receptor in guinea-pig bronchoconstriction. Life Sci 54: PL327–PL332

    Article  PubMed  CAS  Google Scholar 

  • Bonnet J, Kucharczyk N, Robineau P, Lonchampt M, Dacquet C, Regoli D, Fauchere JL, Canet EA (1996) Water-soluble, stable dipeptide NK1 receptor-selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523. Eur J PharmacoI 310: 37–46

    Article  CAS  Google Scholar 

  • Bountra C, Bunce K, Dale T, Gardner C, Jordan C, Twissell D, Ward P (1993) Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 249: R3–R4

    Article  PubMed  CAS  Google Scholar 

  • Boyle S, Guard S, Higginbottom M, Horwell DC, Howson W, McKnight AT, Martin K, Pritchard MC, O’Toole J, Raphy J (1994) Rational design of high affinity tachykinin NK1 receptor antagonists. Bioorg Med Chem 2: 357–370

    Article  PubMed  CAS  Google Scholar 

  • Bremer AA, Tansky FM, Wu M, Boyd ND, Leeman S (2001) Direct evidence for the interaction of neurokinin A with the tachykinin NK1 receptor in tissue. Eur J Pharmacol 423: 143–147

    Article  PubMed  CAS  Google Scholar 

  • Bueno L, Fioramonti J, Garcia-Villar R (2000) Pathobiology of visceral pain: molecular mechanisms and therapeutic implications III Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol 278: G670–G676

    CAS  Google Scholar 

  • Caesar M, Seabrook GR, Kemp JA (1993) Block of voltage-dependent sodium currents by the substance P receptor antagonist (±)CP 96,345 in neurons cultured from the rat cortex. J Physiol 459:397P

    Google Scholar 

  • Campbell EA, Gentry C, Patel S, Kidd B, Cruwys S, Fox AJ, Urban L (2000) Oral anti-hyperalgesic and anti-inflammatory activity of NK1 receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. Pain 87: 253–263

    Article  PubMed  CAS  Google Scholar 

  • Cascieri MA, Macleod AM, Underwood D, Shiao LL, Ber E, Sadowski S, Yu H, Merchant KJ, Swain CJ, Strader CD, Fong TM (1994) Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J Biol Chem 269: 6587–6591

    PubMed  CAS  Google Scholar 

  • Cascieri MA, Ber E, Fong TM, Hale JJ, Tang F, Shiao LL, Mills SG, MacCoss M, Sadowski S, Tota MR, Strader CD (1997) Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykin in NK1 receptor antagonist. Eur J Pharmacol 325: 253–261

    Article  PubMed  CAS  Google Scholar 

  • Cellier E, Barbot L, Iyengar S, Couture R (1999) Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol 127: 717–728

    Article  PubMed  CAS  Google Scholar 

  • Cheeta S, Tucci S, Sandhu J, Williams AR, Rupniak NM, File SE (2001) Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HTIA agonist 8-OH-DPAT in the social interaction test in gerbils. Brain Res 915: 170–175

    Article  PubMed  CAS  Google Scholar 

  • Cirillo R, Astolfi M, Conte B, Lopez G, Parlani M, Sacco G, Terracciano R, Fincham CI, Sisto A, Evangelista S, Maggi CA, Manzini S (2001) Pharmacology of MEN 11467: a potent new selective and orally-effective peptidomimetic tachykinin NK1 receptor antagonist. Neuropeptides 35: 137–147

    Article  PubMed  CAS  Google Scholar 

  • Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O’Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides AD, Eldridge K, Gertz BJ (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-l antagonist, L-754,030, with ondansetron for the prevent ion of cisplatin-induced emesis. Eur J Cancer 37: 835–842

    Article  PubMed  CAS  Google Scholar 

  • Constantine JW, Lebel WS, Woody HA (1991) Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-l receptors. Naunyn Schmiedeberg’s Arch Pharmacol 344: 471–477

    Article  CAS  Google Scholar 

  • Coudore’-Civiale MA, Courteix C, Eschalier A and Fialip J (1998) Effect of tachykinin receptor antagonists in experimental neuropathic pain. Eur J Pharmacol 361: 175–184

    Article  PubMed  CAS  Google Scholar 

  • Courteix C, Lavarenne J, Eschalier A (1993) RP-67580, a specific tachykinin NK1 receptor antagonist, relieves chronic hyperalgesia in diabetic rats. Eur J Pharmacol 241: 267–270

    Article  PubMed  CAS  Google Scholar 

  • Croci T, Landi M, Emonds-Alt X, Le Fur G, Maffrand JP, Manara L (1997) Role of tachykinins in castor oil diarrhoea in rats. Br J Pharmacol 121: 375–380

    Article  PubMed  CAS  Google Scholar 

  • Cutrer FM, Moussaoui S, Garret C, Moskowitz MA (1995) The non-peptide neurokinin-1 antagonist, RPR 100893, Decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience 64: 741–750

    Article  PubMed  CAS  Google Scholar 

  • Delay-Goyet P, Lundberg JM (1991) Cigarette smoke-induced airway oedema is blocked by the NK-l antagonist, CP 96,345. Eur J Pharmacol 203: 157–158

    Article  PubMed  CAS  Google Scholar 

  • Delay-Goyet P, Franco-Cereceda A, Gonsalves SF, Clingan CA, Lowe JA 3rd, Lundberg JM (1992) CP-96,345 antagonism of NK1 receptors and smoke-induced protein extravasation in relation to its cardiovascular effects. Eur J Pharmacol 222: 213–218

    Article  PubMed  CAS  Google Scholar 

  • Diemunsch P, Schoeffler P, Bryssine B, Cheli-Muller LE, Lees J, McQuade BA, Spraggs CF (1999) Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth 82: 274–276

    Article  PubMed  CAS  Google Scholar 

  • Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, MacLean DB (1998) The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 64: 562–568

    Article  PubMed  CAS  Google Scholar 

  • Doi T, Kamo I, Imai S, Okanishi S, Ishimaru T, Ikeura Y, Natsugari H (1999) Effects of TAK-637, a tachykinin receptor antagonist, on lower urinary tract function in the guinea-pig. Eur J Pharmacol 383: 297–303

    Article  PubMed  CAS  Google Scholar 

  • Doi T, Kamo I, Imai S, Okanishi S, Ikeura Y, Natsugari H (2000) Effects of TAK-637, a tachykinin receptor antagonist, on the micturition reflex in guinea-pigs. Eur J Pharmacol 395: 241–246

    Article  PubMed  CAS  Google Scholar 

  • Eglezos A, Giuliani S, Viti G, Maggi CA (1991) Direct evidence that capsaicin-induced plasma protein extravasation is mediated through tachykinin NK1receptors. Eur J Pharmacol 209: 277–279

    Article  PubMed  CAS  Google Scholar 

  • Emonds-Alt X, Doutremepuich J, Heaulme M, Neliat G, Santucci V, Steinberg R, Vilain P, Bichon D, Ducoux J, Proietto V, Van Broeck D, Soubrié P, Le Fur G and Breliere, J (1993) In vitro and in vivo biological activities of SR140333, a novel potent non-peptide NK1 receptor antagonist. Eur J Pharmacol 250: 403–413

    Article  PubMed  CAS  Google Scholar 

  • Emonds-Alt X, Proietto V, Steinberg R, Oury-Donat F, Vige X, Vilain P, Naline E, Daoui S, Advenier C, Le Fur G, Maffrand JP, Soubrie P, Pascal M (2002) SSR240600 [(R)-2-(1-[2[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-l receptor: I biochemical and pharmacological characterization. J Pharmacol Exp Ther 303: 1171–1179

    Article  PubMed  CAS  Google Scholar 

  • Evangelista S (2001) Eziopitant. Curr Opin Invest Drugs 2: 1441–1443

    CAS  Google Scholar 

  • Fahy JV, Wong HH, Geppetti P, Reis JM, Harris SC, Maclean DB, Nadel JA Boushey HA (1995) Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Resp Crit Care Med 152: 879–884

    PubMed  CAS  Google Scholar 

  • Fardin V, Carruette A, Menager J, Bock M, Flamand O, Foucault F, Heuillet E, Moussaoui SM, Tabart M, Peyronel JF, Garret C (1994) In vitro pharmacological properties of RPR 100,893, a novel nonpeptide antagonist of the human NK1 receptor. Neuropeptides 26: 34

    Article  Google Scholar 

  • Folkers K, Hakanson R, Horig J, Xu JC, Leander S (1984) Biological evaluation of substance P antagonists. Br J Pharmacol 83: 449–456

    Article  PubMed  CAS  Google Scholar 

  • Folkers K, Feng DM, Asano N, Hakanson R, Weisenfeld-Hallin Z, Leander S (1990) Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci USA 87: 4833–4835

    Article  PubMed  CAS  Google Scholar 

  • Fong TM, Yu H, Strader C (1992) Molecular bases for the species selectivity of the NK1 receptor antagonists CP 96,345 and RP 67,580. J Biol Chem 267: 25668–25671

    PubMed  CAS  Google Scholar 

  • Fong TM, Yu H, Cascieri MA, Underwood D, Swian CJ, Strader CD (1994) The role of Histidine 265 in antagonist binding to the NK1 receptor. J Biol Chem 269: 2728–2732

    PubMed  CAS  Google Scholar 

  • Fujii T, Murai M, Morimoto H, Maeda Y, Yamaoka M, Hagiwara D, Miyake H, Ikari N, Matsuo M (1992) Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888. Br J Pharmacol 107: 785–789

    Article  PubMed  CAS  Google Scholar 

  • Gardner CJ, Twissell DJ, Dale TJ, Gale JD, Jordan CC, Kilpatrick GJ, Bountra C, Ward P (1995) The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol 116: 3158–3163

    Article  PubMed  CAS  Google Scholar 

  • Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P (1996) GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 65: 45–53

    Article  PubMed  CAS  Google Scholar 

  • Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel JF, Blanchard JC, Laduron PM (1991) Pharmacological properties of a potent and selective nonpeptide SP antagonist. Proc Natl Acad Sci USA 88: 10208–10211

    Article  PubMed  CAS  Google Scholar 

  • Gentsch C, Cutler M, Vassout A, Veenstra S, Brugger F (2002) Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils. Behav Brain Res 133: 363–368

    Article  PubMed  CAS  Google Scholar 

  • Gesztesi Z, Song D, White PF (1998) Comparison of a new NK-l antagonist (CP-122,72l) to ondansetron in the prevention of post-operative nausea and vomiting. Anesth Anal 86: S32

    Article  Google Scholar 

  • Gesztesi Z, Scuderi PE, White PF, Wright W, Wender RH, D’Angelo R, Black LS, Dalby PL, MacLean D (2000) Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 93: 931–937

    Article  PubMed  CAS  Google Scholar 

  • Gether U, Lowe JA 3rd, Schwartz TW (1995) Tachykinin non-peptide antagonists: binding domain and molecular mode of action. Biochem Soc Trans 23: 96–102

    PubMed  CAS  Google Scholar 

  • Gitter BD, Waters DC, Bruns RF, Mason NR Nixon JA, Howbert JJ (1991) Species differences in affinities of nonpeptide antagonists for SP receptors. Eur J Pharmacol 197: 237–238

    Article  PubMed  CAS  Google Scholar 

  • Gitter BD, Bruns RF, Howbert JJ, Waters DC, Threlkeld PG, Cox LM, Nixon JA, Lobb KL, Mason NR, Stengel PW, Cockerham SL, Silbaugh SA, Gehlert DR, Schober DA, Iyengar S, Calligaro DO, Regoli D, Hipskind PA (1995) Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-l ) receptor antagonist. J Pharmacol Exp Ther 275: 737–744

    PubMed  CAS  Google Scholar 

  • Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrota DJ, Iyengar S (2000) Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther 67: 419–426

    Article  PubMed  CAS  Google Scholar 

  • Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P, Johnson KW, Ryan RE Jr (2001a) Lanepitant, an NK-l antagonist, in migraine prevention. Cephalalgia 21: 102–106

    Article  PubMed  CAS  Google Scholar 

  • Goldstein DJ, Wang O, Gitter BD, Iyengar S (2001b) Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol 24: 16–22

    Article  PubMed  CAS  Google Scholar 

  • Gonsalves S, Watson J, Ashton C (1996) Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets. Eur J Pharmacol 305: 181–185

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez MI, Field MJ, Holloman EF, Hughes J, Oles RJ, Singh L (1998) Evaluation of PD 154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain. Eur J Pharmacol 344: 115–120

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez MI, Field MJ, Hughes J, Singh L (2000) Evaluation of selective NH1 receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 294: 444–450

    PubMed  CAS  Google Scholar 

  • Guard S, Watson SP (1991) Tachykinin receptor types: classification and membrane signalling mechanisms. Neurochem Int 18: 149–165

    Article  PubMed  CAS  Google Scholar 

  • Guard S, Boyle SJ, Tang KW, Watling KJ, McKnight AT, Woodruff GN (1993) The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences. Br J Pharmacol 110: 385–391

    Article  PubMed  CAS  Google Scholar 

  • Guo JZ, Yoshioka K, Zhao FY, Hosoki R, Maehara T, Yanagisawa M, Hagan RM, Otsuka M (1995) Pharmacological characterization of GR82334, a tachykinin NK1 receptor antagonist, in the isolated spinal cord of the neonatal rat. Eur J Pharmacol 281: 49–54

    Article  PubMed  CAS  Google Scholar 

  • Hagan RM, Ireland SJ, Jordan CC, Beresford IJM, Stephens-Smith ML, Ewan G, Ward P (1990) GR 71251, a novel, potent and highly selective antagonist at neurokinin NK-1 receptors. Br J Pharmacol 99:62P

    Google Scholar 

  • Hagan RM, Ireland SJ Bailey F, Mcbride C, Jordan CC, Ward, P (1991) A spirolactam conformationally-constrained analogue of physalaemin which is a peptidase-resistant selective neurokinin NK1 receptor antagonist. Br J Pharmacol 102:168P

    Google Scholar 

  • Hagiwara D, Miyake H, Igari N, Murano K, Morimoto H, Murai M, Fujii T, Matsuo M (1993) Design of a novel dipeptide substance P antagonist FK888. Regul Pept 46: 332–334

    Article  PubMed  CAS  Google Scholar 

  • Hale JJ, Mills SG, MacCoss M, Shah SK, Qi H, Mathre DJ, Cascieri MA, Sadowski S, Strader CD, MacIntyre DE, Metzger JM (1996) 2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-l receptor antagonist. J Med Chem 39: 1760–1762

    Article  PubMed  CAS  Google Scholar 

  • Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, Ber E, Chicchi GG, Kurtz M, Metzger J, Eiermann G, Tsou NN, Tattersall FD, Rupniak NM, Williams AR, Rycroft W, Hargreaves R, MacIntyre DE (1998) Structural optimization affording 2(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro )phenyl-4-(3-oxo1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-l receptor antagonist. J Med Chem 41: 4607–4614

    Article  PubMed  CAS  Google Scholar 

  • Hale JJ, Mills SG, MacCoss M, Dorn CP, Finke PE, Budhu RJ, Reamer RA, Huskey SE, Luffer-Atlas D, Dean BJ, McGowan EM, Feeney WP, Chiu SH, Cascieri MA, Chicchi GG, Kurtz MM, Sadowski S, Ber E, Tattersall FD, Rupniak NM, Williams AR, Rycroft W, Hargreaves R, Metzger JM, MacIntyre DE (2000) Phosphorylated morpholine acetal human neurokinin-l receptor antagonists as water-soluble prodrugs. J Med Chem 43: 1234–1241

    Article  PubMed  CAS  Google Scholar 

  • Hall JM, Mitchell D, Morton IK (1994) Typical and atypical NK1 tachykinin receptor characteristics in the rabbit isolated iris sphincter. Br J Pharmacol 112: 985–991

    Article  PubMed  CAS  Google Scholar 

  • Harrison T, Williams BJ, Swain CJ, Ball RG (1994) Piperidine-ether based hNK1 antagonists 1: determination of the relative and absolute stereochemical requirements. Biomed Chem Lett 4: 2545–2550

    Article  CAS  Google Scholar 

  • Hastrup H, Schwartz TW (1996) Septide and neurokinin A are high affinity ligands on the NK1 receptor:evidence from homologus versus heterologus binding analysis. FEBS Lett 399: 264–266

    Article  PubMed  CAS  Google Scholar 

  • Hauser K, Heid J, Criscione L, Brugger F, Ofner S, Veenstra S, Schilling W (1994) CGRP 49,823, a novel, nonpeptidic NK1 receptor antagonist: in vitro pharmacology. Neuropeptides 26: 37

    Article  Google Scholar 

  • Hesketh PJ, Gralla RJ, Webb RT, Veno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL (1999) Randomized phase II study of the neurokinin 1 receptor antagonist CJ-ll,974 in the control of cisplatin-induced emesis. J Clin Oncol 17: 338–343

    PubMed  CAS  Google Scholar 

  • Hill R (2000a) NK1 (substance P) receptor antagonists-why are they not analgesic in humans? Trends Pharmacol Sci 21: 244–246

    Article  PubMed  CAS  Google Scholar 

  • Hill R (2000b) Reply: will changing the testing paradigms show that NK1 receptor antagonists are analgesic in humans? Trends Pharmacol Sci 21: 465

    Article  CAS  Google Scholar 

  • Hipskind PA, Howbert JJ, Bruns RF, Cho SS, Crowell TA, Foreman MM, Gehlert DR, Iyengar S, Johnson KW, Krushinski JH, Li DL, Lobb KL, Mason NR, Muehl BS, Nixon JA, Phebus LA, Regoli D, Simmons RM, Threlkeld PG, Waters DC, Gitter BD (1996) 3Aryl-l,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J Med Chem 39: 736–748

    Article  PubMed  CAS  Google Scholar 

  • Hirayama Y, Lei YH, Barnes PJ, Rogers DF (1993) Effects of two novel tachykinin antagonists, FK224 and FK888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guinea-pigs in vivo. Br J Pharmacol 108: 844–851

    Article  PubMed  CAS  Google Scholar 

  • Hökfelt T, Vincent S, Hellsten L, Rosell S, Folkers K, Markey K, Goldstein M, Cuello C (1981) Immunohistochemical evidence for a ‘neurotoxic’ action of (D-Pro2, D-Trp7,9)-substance P, an analogue with substance P antagon istic activity. Acta Physiol Scand 113: 571–573

    Article  PubMed  Google Scholar 

  • Holzer P (1998) Tachykinins as targets of gastroenterological pharmacotherapy. Drugs News Perspect 11: 394–401

    Article  CAS  Google Scholar 

  • Holzer P, Holzer-Petsche U (1997) Tachykinins in the gut Part II Roles in neural excitation, secretion and inflammation. Pharmacol Ther 73: 219–263

    Article  PubMed  CAS  Google Scholar 

  • Holzer-Petsche U, Rordorf-Nikolic T (1995) Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception. Br J Pharmacol 115: 486–490

    Article  PubMed  CAS  Google Scholar 

  • Hoover DB(1991) Effects of spantide on guinea-pig coronary resistance vessels. Peptides 12: 983–988

    Article  PubMed  CAS  Google Scholar 

  • Huang R-RC, Yu H, Strader CD, Fong TM (1994) Interaction of substance P with the second and seventh transmembrane domain of the NK1 receptor. Biochemistry 33: 3007–3013

    Article  PubMed  CAS  Google Scholar 

  • Ichinose M, Miura M, Yamauchi H, Kageyama N, Tomaki M, Oyake T, Ohuchi Y, Hida W, Miki H, Tamura G, Shirato K (1996) A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Resp Crit Care Med 153: 936–941

    PubMed  CAS  Google Scholar 

  • Inoue H, Nagata N, Koshihara Y (1996) Effect of the tachykinin receptor antagonists, SR 140333, FK 888, and SR 142801, on capsaicin-induced mouse ear oedema. Inflamm Res 45: 303–307

    Article  PubMed  CAS  Google Scholar 

  • Iyengar S, Hipskind PA, Gehlert DR, Schober D, Lobb KL, Nixon JA, Helton DR, Kallman MJ, Boucher S, Couture R, Li DL, Simmons RM (1997) LY303870, a centrally active neurokinin-l antagonist with a long duration of action. J Pharmacol Exp Ther 280: 774–785

    PubMed  CAS  Google Scholar 

  • Jenkinson KM, Southwell BR, Furness JB (1999) Two affinities for a single antagonist at the neuronal NK1 tachykinin receptor: evidence from quantitation of receptor endocytosis. Br J Pharmacol 126: 131–136

    Article  PubMed  CAS  Google Scholar 

  • Jung M, Calassi R, Maruani J, Barnouin MC, Souilhac J, Poncelet M, Gueudet C, Emonds Alt X, Soubrie P, Breliere JC (1994) Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptors. Neuropharmacology 33: 167–179

    Article  PubMed  CAS  Google Scholar 

  • Karlsson U, Nasstrom J, Berge OG (1994) (+/-)-CP-96,345, an NK1 receptor antagonist, has local anaesthetic-like effects in a mammalian sciatic nerve preparation. Regul Pept 52: 39–46

    Article  PubMed  CAS  Google Scholar 

  • Khan S, Liu YC, Khawaja AM, Manzini S, Rogers DF (2001) Effect of the long-acting tachykinin NK1 receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. Br J Pharmacol 132: 189–196

    Article  PubMed  CAS  Google Scholar 

  • Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640–1645

    Article  PubMed  CAS  Google Scholar 

  • Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ (1997) Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 89: 817–818

    Article  PubMed  CAS  Google Scholar 

  • Lei YH, Barnes PJ, Rogers DF (1992) Inhibition of neurogenic plasma exudation in guinea-pig airways by CP-96,345, a new non-peptide NK1 receptor antagonist. Br J Pharmacal 105: 261–262

    Article  CAS  Google Scholar 

  • Leander S, Hakanson R, Rosell S, Folkers K, Sundler F, Tornqvist K (1981) A specific SP antagonist blocks smooth muscle contractions induced by noncholinergic nonadrenergic nerve stimulation. Nature 294: 467–469

    Article  PubMed  CAS  Google Scholar 

  • Lecci A, Giuliani S, Patacchini R, Viti G, Maggi CA (1991) Role of NK1 tachykinin receptors in thermonociception: effect of (±)-CP 96,345, a non peptide substance P antagonist on the hot plate test in mice. Neurosci Letters 129: 299–302

    Article  CAS  Google Scholar 

  • Lee OY, Munakata J, Naliboff, BD, Chang L, Mayer E (2000) A double blind parallel group pilot study of the effects of CJ-11, 974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology 118: 4439

    Google Scholar 

  • Lee WS, Moussaoui SM, Moskowitz MA (1994) Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacal 112: 920–924

    Article  CAS  Google Scholar 

  • Lernbeck F, Donnerer J, Tsuchiya M, Nagahisa A (1992) The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol 105: 527–530

    Article  Google Scholar 

  • Lombet A, Spedding M (1994) Differential effects of nonpeptidic tachykinin receptor antagonists on Ca2+ channels. Eur J Pharrnacol 267: 113–115

    Article  CAS  Google Scholar 

  • Longmore J, Razzaque Z, Shaw D, Hill RG (1994) Differences in the effects of Nk1-receptor antagonists, (+/−)-CP 96,345 and CP 99,994, on agonist-induced responses in guinea-pig trachea. Br J Pharmacol 112: 176–178

    Article  PubMed  CAS  Google Scholar 

  • Lowe JA 3rd, Drozda SE, Snider RM, Longo KP, Zorn SH, Morrone J, Jackson ER, McLean S, Bryce DK, Bordner J (1992) The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N[(2-methoxyphenyl)methyl]-1-azabicyclo[222]-octan-3-amine as a novel, nonpeptide substance P antagonist. J Med Chem 35: 2591–2600

    Article  PubMed  CAS  Google Scholar 

  • Lucot JB, Obach RS, McLean S, Watson JW (1997) The effect of CP-99994 on the responses to provocative motion in the cat. Br J Pharmacol 120: 116–120

    Article  PubMed  CAS  Google Scholar 

  • MacLeod AM, Merchant KJ, Brookfield F, Kelleher F, Stevenson G, Owens AP, Swain CJ, Casiceri MA, Sadowski S, Ber E (1994) Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. J Med Chem 37: 1269–1274

    Article  PubMed  CAS  Google Scholar 

  • MacLeod AM, Cascieri MA, Merchant KJ, Sadowski S, Hardwicke S, Lewis RT, MacIntyre DE, Metzger JM, Fong TM, Shepheard S (1995) Synthesis and biological evaluation of NK1 antagonists derived from L-tryptophan. J Med Chem 38: 934–941

    Article  PubMed  CAS  Google Scholar 

  • Maggi CA (1995) The mammalian tachykinin receptors. Gen Pharmacol 26: 911–944

    Article  PubMed  CAS  Google Scholar 

  • Maggi CA, Schwartz TW (1997) The dual nature of the tachykinin NK1 receptor. Trends Pharmacol Sci 18: 351–355

    PubMed  CAS  Google Scholar 

  • Maggi CA, Patacchini R, Feng DM, Folkers K (1991) Activity of spantide I and II at various tachykinin receptors and NK-2 tachykinin receptor subtypes. Eur J Pharmacol 199: 127–129

    Article  PubMed  CAS  Google Scholar 

  • Maggi CA, Giuliani S, Patacchini R, Santicioli P, Theodorsson E, Barbanti G, Turini D, Giachetti A (1992) Tachykinin antagonists inhibit nerve-mediated contractions in the circular muscle of the human ileum. Gastroenterology 102: 88–96

    PubMed  CAS  Google Scholar 

  • Maggi CA, Patacchini R, Meini S, Giuliani S (1993a) Evidence for the presence of a septide-sensitive tachykinin receptor in the circular muscle of the guinea-pig ileum. Eur J Pharmacol 235: 309–311

    Article  PubMed  CAS  Google Scholar 

  • Maggi CA, Patacchini R, Rovero P, Giachetti A (1993b) Tachykinin receptors and tachykinin receptor subtypes. J Autonom Pharmacol 13: 23–93

    Article  CAS  Google Scholar 

  • Maggi CA, Patacchini R, Meini S, Quartara L, Sisto A, Potier E, Giuliani S, Giachetti A (1994) Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon. Br J Pharmacol 112: 150–160

    Article  PubMed  CAS  Google Scholar 

  • Mazelin L, Theodorou V, More J, Emonds-Alt X, Fioramonti J and Bueno L (1998) Comparative effects onf nonpeptide tachykinin receptor antagonists in experimental gut inflammation in rats and guinea-pigs. Life Sci 63: 293–304

    Article  PubMed  CAS  Google Scholar 

  • McAllister KH, Pratt JA (1998) GR205171 blocks apomorphine and amphetamine-induced conditioned taste aversions Eur J Pharmacol 353: 141–148

    Article  PubMed  CAS  Google Scholar 

  • McKnight AT, Boyle SJ, Tang K-W, Hill DR, Sauman-Chauhan N, Woodruff GN (1994) Functional activity at NK1 receptors of novel peptoid antagonists. Br J Pharmacol 111:49P

    Google Scholar 

  • McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Reynolds LS, Robinson G, Schmidt AW, Siok C, Heym J (1993) Pharmacology of CP99,994; a nonpeptide antagonist of the tachykinin neurokinin-l receptor. J Pharmacol Exp Ther 267: 472–479

    PubMed  CAS  Google Scholar 

  • McLean S, Ganong A, Seymour PA, Bryce DK, Crawford RT, Morrone J, Reynolds LS, Schmidt AW, Zorn S, Watson J, Fossa A, DePasquale M, Rosen T, Nagahisa A, Tsuchiya M, Heym J (1996) Characterization of CP-122, 721; a nonpeptide antagonist of the neurokinin NK1 receptor. J Pharmacol Exp Ther 277: 900–908

    PubMed  CAS  Google Scholar 

  • Megens AA, Ashton D, Vermeire JC, Vermote PC, Hens KA, Hillen LC, Fransen JF, Mahieu M, Heylen L, Leysen JE, Jurzak MR, Janssens F (2002) Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-l receptor antagonist. J Pharmacol Exp Ther 302: 696–709

    Article  PubMed  CAS  Google Scholar 

  • Meini S, Patacchini R, Maggi CA (1994) Tachykinin NK1 receptor subtypes in the rat urinary bladder. Br J Pharmacol 111: 739–746

    Article  PubMed  CAS  Google Scholar 

  • Minami M, Endo T, Kikuchi K, Ihira E, Hirafuji M, Hamaue N, Monma Y, Sakurada T, Tan-no K, Kisara K (1998) Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret. Eur J Pharmacol 363: 49–55

    Article  PubMed  CAS  Google Scholar 

  • Montier F, Carruette A, Moussaoui S, Boccio D, Garret C (1994) Antagonism of substance P and related peptides by RP 67580 and CP-96,345, at tachykinin NK1 receptor sites, in the rat urinary bladder. Eur J Pharmacol 251: 9–14

    Article  PubMed  CAS  Google Scholar 

  • Moriarty D, Goldhill J, Selve N, O’Donoghue DP, Baird AW (2001) Human colonic antisecretory activity of the potent NK1 antagonist, SR140333: assessment of potential anti-diarrhoeal activity in food allergy and inflammatory bowel disease. Br J Pharmacol 133: 1346–1354

    Article  PubMed  CAS  Google Scholar 

  • Morimoto H, Murai M, Maeda Y, Hagiwara D, Miyake H, Matsuo M, Fujii T (1992) FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity. Br J Pharmacol 106: 123–126

    Article  PubMed  CAS  Google Scholar 

  • Moussaoui SM, Montier F, Carruette A, Blanchard JC, Laduron PM, Garret C A (1993) non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically. Br J Pharmacol 109: 259–264

    Article  PubMed  CAS  Google Scholar 

  • Moussaoui SM, Montier F, Carruette A, Fardin V, Floch A, Garret C (1994) In vivo pharmacological properties of RPR 100893, a novel non-peptide antagonist of the human NK1 receptor. Neuropeptides 26: 35

    Article  Google Scholar 

  • Murai M, Morimoto H, Maeda Y, Fujii T (1992) Effects of the tripeptide substance P antagonist, FR113680, on airway constriction and airway edema induced by neurokinins in guinea-pigs. Eur J Pharmacol 217: 23–29

    Article  PubMed  CAS  Google Scholar 

  • Murai M, Maeda Y, Hagiwara D, Miyake H, Ikari N, Matsuo M, Fujii T (1993) Effects of an NK1 receptor antagonist, FK888, on constriction and plasma extravasation induced in guinea-pig airway by neurokinins and capsaicin. Eur J Pharmacol 236: 7–13

    Article  PubMed  CAS  Google Scholar 

  • Mussap CJ, Geraghty DP, Burcher E (1993) Tachykinin receptors: a radioligand binding perspective. J Neurochem 6: 1987–2009

    Article  Google Scholar 

  • Nagahisa A, Kanai Y, Suga O, Taniguchi K, Tsuchiya M, Lowe JA 3rd, Hess HJ (1992) Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist. Eur J Pharmacol 217: 191–195

    Article  PubMed  CAS  Google Scholar 

  • Natsugari H, Ikeura Y, Kiyota Y, Ishichi Y, Ishimaru T, Saga O, Shirafuji H, Tanaka T, Kamo I, Doi T (1995) Novel, potent, and orally active substance P antagonists: synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3,4b] pyridine. J Med Chem 38: 3106–3120

    Article  PubMed  CAS  Google Scholar 

  • Natsugari H, Ikeura Y, Kamo I, Ishimaru T, Ishichi Y, Fujishima A, Tanaka T, Kasahara F, Kawada M, Doi T (1999) Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK1 receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions. J Med Chem 42: 3982–3993

    Article  PubMed  CAS  Google Scholar 

  • Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin—receptor antagonist. New Engl J Med 340: 190–195

    Article  PubMed  CAS  Google Scholar 

  • Okano S, Nagaya H, Ikeura Y, Natsugari H, Inatomi N (2001) Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. J Pharmacol Exp Ther 298: 559–564

    PubMed  CAS  Google Scholar 

  • Okano S, Ikeura Y, Inatomi N (2002) Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther 300: 925–931

    Article  PubMed  CAS  Google Scholar 

  • Palma C, Goso C, Manzini S (1994) Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line. Neurosci Lett 171: 221–224

    Article  PubMed  CAS  Google Scholar 

  • Papp M, Vassout A, Gentsch C (2000) The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 115: 19–23

    Article  PubMed  CAS  Google Scholar 

  • Patacchini R, Maggi CA (1995) Tachykinin NK1 receptors mediate both vasoconstrictor and vasodilator responses in the rabbit isolated jugular vein Eur J Pharmacol 283: 233–240

    Article  PubMed  CAS  Google Scholar 

  • Patacchini R, Santicioli P Astolfi M Rovero P, Viti G & Maggi CA (1992) Activity of peptide and non-peptide antagonists at peripheral NK-l tachykinin receptors. Eur J Pharmacol 215: 93–98

    Article  PubMed  CAS  Google Scholar 

  • Patacchini R, Quartara L, Astolfi M, Goso C, Giachetti A, Maggi CA (1995) Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors. J Pharmacol Exp Ther 272: 1082–1087

    PubMed  CAS  Google Scholar 

  • Patacchini R, Bartho L, Maggi CA (1997) Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct. Br J Pharmacol 122: 1633–1638

    Article  PubMed  CAS  Google Scholar 

  • Petitet F, Saffroy M, Torrens Y, Lavielle S, Chassaing G, Loeuillet D, Glowinski J & Beaujouan JC (1992) Possible existence of a new tachykinin receptor subtype in the guinea-pig ileum. Peptides 13: 383–388

    Article  PubMed  CAS  Google Scholar 

  • Phebus LA, Johnson KW, Stengel PW, Lobb KL, Nixon JA, Hipskind PA (1997) The nonpeptide NK-l receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea-pigs. Life Sci 60: 1553–1561

    Article  PubMed  CAS  Google Scholar 

  • Piedimonte G, Bertrand C, Geppetti P, Snider RM, Desai MC, Nadel JA (1993) A new NK1 receptor antagonist (CP-99,994) prevents the increase in tracheal vascular permeability produced by hypertonic saline. J Pharmacol Exp Ther 266: 270–273

    PubMed  CAS  Google Scholar 

  • Pradier L, Menager J, Le Guern J, Bock MD, Heuillet E, Fardin V, Garret C, Doble A, Mayaux JF (1994) Septide: an agonist for the NK1 receptor acting at a site distinct from substance P. Mol Pharmacol 45: 287–93

    PubMed  CAS  Google Scholar 

  • Quartara L, Maggi CA (1997) The tachykinin NK-l receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 31: 537–553

    Article  PubMed  CAS  Google Scholar 

  • Quartara L, Maggi CA (1998) The tachykinin NK-1 receptor. Part II: distribution and pathopysiological roles. Neuropeptides 32: 1–49

    Article  PubMed  CAS  Google Scholar 

  • Radhakrishnan V, Henry JL (1991) Novel substance P antagonist, CP-96,345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P. Neurosci Lett 132: 39–43

    Article  PubMed  CAS  Google Scholar 

  • Regoli D, Escher E, Drapeau G, D’Orleans-Iuste P, Mizrahi J (1984) Receptors for substance P III Classification by competitive antagonists. Eur J Pharmacol 97: 179–189

    Article  PubMed  CAS  Google Scholar 

  • Regoli D, Drapeau G, Dion S, D’Orleans-Iuste P (1989) Receptors for substance P and related neurokinins. Pharmacology 38: 1–15

    Article  PubMed  CAS  Google Scholar 

  • Regoli D, Boudon A and Fauchere J (1994) Receptors and antagonists for substance P and related peptides. Pharmacal Rev 46: 551–599

    CAS  Google Scholar 

  • Reid K, Palmer JL, Wright RJ, Clemes SA, Troakes C, Somal HS, House F, Stott JR (2000) Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 50: 61–64

    Article  PubMed  CAS  Google Scholar 

  • Romerio SC, Linder L, Haefeli WE (1999) Neurokinin-l receptor antagonist R116301 inhibits substance P-induced venodilation. Clin Pharmacol Ther 66: 522–527

    Article  PubMed  CAS  Google Scholar 

  • Rupniak NMJ, Kramer MS (1999) Discovery of the anti-depressant and anti-emetic efficacy of substance Preceptor (NK1) antagonists. Trends Pharmacol Sci 20: 485–489

    Article  PubMed  CAS  Google Scholar 

  • Rupniak NM, Boyce S, Williams AR, Cook G, Longmore J, Seabrook GR, Caeser M, Iversen SD, Hill RG (1993) Antinociceptive activity of NK1 receptor antagonists: nonspecific effects ofracemic RP67580. Br J Pharmacol 110: 1607–1613

    Article  PubMed  CAS  Google Scholar 

  • Rupniak NM, Webb JK, Williams AR, Carlson E, Boyce S, Hill RG (1995) Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP-99,994, in conscious gerbils. Br J Pharmacol 116: 1937–1943

    Article  PubMed  CAS  Google Scholar 

  • Rupniak NM, Carlson E, Boyce S, Webb JK, Hill RG (1996) Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain 67: 189–195

    Article  PubMed  CAS  Google Scholar 

  • Rupniak NM, Tattersall FD, Williams AR, Rycroft W, Carlson EJ, Cascieri MA, Sadowski S, Ber E, Hale JJ, Mills SG, MacCoss M, Seward E, Huscroft I, Owen S, Swain CJ, Hill RG, Hargreaves RJ (1997) In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. Eur J Pharmacol 326: 201–209

    Article  PubMed  CAS  Google Scholar 

  • Sachais BS, Krause JE (1994) Both extracellular and transmembrane residues contribute to the species selectivity of the neurokinin-l receptor antagonist WIN 51708. Mol Pharmacol 46: 122–128

    PubMed  CAS  Google Scholar 

  • Sachais BS, Snider RM, Lowe JA 3rd, Krause JE (1993) Molecular basis for the species selectivity of the substance P antagonist CP-96,345. J Biol Chem 268: 2319–23

    PubMed  CAS  Google Scholar 

  • Sakurada T, Manome Y, Tan-No K, Sakurada S, Kisara K, Ohba M, Terenius LA (1992) Selective and extremely potent antagonist of the neurokinin-l receptor. Brain Res 593: 319–322

    Article  PubMed  CAS  Google Scholar 

  • Sakurada T, Katsumata K, Yogo H, Tan-No K, Sakurada S, Kisara K (1993) Antinociception induced by CP 96,345, a non-peptide NK-1 receptor antagonist, in the mouse formalin and capsaicin tests. Neurosci Lett 151: 142–145

    Article  PubMed  CAS  Google Scholar 

  • Sakurada T, Katsumata K, Yogo H, Tan-No K, Sakurada S, Ohba M, Kisara K (1995) The neurokinin-1 receptor antagonist, sendide, exhibits antinociceptive activity in the formalin test. Pain 60: 175–180

    Article  PubMed  CAS  Google Scholar 

  • Schmidt AW, McLean S, Heym J (1992) The substance P receptor antagonist CP-96,345 interacts with Ca 2+ channels. Eur J Pharmacol 219: 491–492

    Article  PubMed  CAS  Google Scholar 

  • Schwartz TW, Gether U, Schambye HT, Hjorth SA (1995) Molecular mechanisms of action of nonpeptide ligands for peptide receptors. Curr Pharmac Design 1: 325–342

    CAS  Google Scholar 

  • Seabrook GR, Shepheard SL, Williamson DJ, Tyrer P, Rigby M, Cascieri MA, Harrison T, Hargreaves RJ, Hill RG (1996) L-733,060,a novel tachykinin NK1, receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol 317: 129–135

    Article  PubMed  CAS  Google Scholar 

  • Shepheard SL, Williamson DJ, Hill RG, Hargreaves RJ (1993) The non-peptide neurokininl receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater ofrats. Br J Pharmacol 108: 11–12

    Article  PubMed  CAS  Google Scholar 

  • Singh L, Field MJ, Hughes J, Kuo BS, Suman-Chauhan N, Tuladhar BR, Wright DS, Naylor RJ (1997) The tachykinin NK1, receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. Eur J Pharmacol 321: 209–216

    Article  PubMed  CAS  Google Scholar 

  • Smith G, Harrison S, Bowers J, Wiseman J, Birch P (1994) Non-specific effects of the tachykinin NK1 receptor antagonist, CP-99,994, in antinociceptive tests in rat, mouse and gerbil. Eur J Pharmacol 271: 481–487

    Article  PubMed  Google Scholar 

  • Snider RM, Constantine JW, Lowe III JA, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW Hess HJ (1991) A potent nonpeptide antagonist of the SP (NK-1) receptor. Science 251: 435–437

    Article  PubMed  CAS  Google Scholar 

  • Sonea IM, Palmer MV, Akili D, Harp JA (2002) Treatment with neurokinin-1 receptor antagonist reduces severity of inflammatory bowel disease induced by Cryptosporidiurn parvum. Clin Diagn Lab Immunol 9: 333–340

    PubMed  CAS  Google Scholar 

  • Steinberg R, Alonso R, Rouquier L, Desvignes C, Michaud JC, Cudennec A, Jung M, Simiand J, Griebel G, Emonds-Alt X, Le Fur G, Soubrie P (2002) SSR240600 [(R)-2(1-[2-[4-[2-[3,5-bis(trifluoromethy1)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl] ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II Neurochemical and behavioral characterization. J Pharmacol Exp Ther 303: 1180–1188

    Article  PubMed  CAS  Google Scholar 

  • Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J, Shebani K, Moore F, O’Brien M, Becker JM (2000) NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol 279: G1298–G1306

    CAS  Google Scholar 

  • Suarez GA, Opfer-Gehrking TL, McLean DB (1994) Double-blind, placebo-controlled study of the efficacy of a substance P (NK1 ) receptor antagonist in painful peripheral neuropathy. Neurology 44: A220

    Article  Google Scholar 

  • Swain CJ, Seward EM, Sabin V, Cascieri MA (1993) Quinuclidine based NK-1 antagonists 2: determination of the absolute stereochemical requirements. Biomed Chem Lett 3: 1703–1706

    Article  CAS  Google Scholar 

  • Tamura K, Mutabagani K, Wood JD (1993) Analysis of a nonpeptide antagonist for substance P on myenteric neurons of guinea-pig small intestine. Eur J Pharmacol 232: 235–239

    Article  PubMed  CAS  Google Scholar 

  • Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG (1993) The tachykinin NK1, receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 250: R5–R6

    Article  PubMed  CAS  Google Scholar 

  • Tattersall FD, Rycroft W, Marmont N, Cascieri M, Hill RG, Hargreaves RJ (1995) Enantiospecific inhibition of emesis induced by nicotine in the house musk shrew (Suncus murinus) by the neurokinin 1 (NK1) receptor antagonist CP-99,994. Neuropharmacology 34: 1697–1699

    Article  PubMed  CAS  Google Scholar 

  • Torrens Y, Beaujouan JC, Saffroy M, Glowinski J (1995) Involvement of septide-sensitive tachykinin receptors in inositol phospholipid hydrolysis in the rat urinary bladder. Peptides 16: 587–594

    Article  PubMed  CAS  Google Scholar 

  • Towler PK, Brain SD (1998) Activity of tachykinin NK1 and bradykinin B2 receptor antagonists, and an opioid ligand at different stimulation parameters in neurogenic inflammation in the rat. Neurosci Lett 257: 5–8

    Article  PubMed  CAS  Google Scholar 

  • Tsuchiya M, Fujiwara Y, Kanai Y, Mizutani M, Shimada K, Suga O, Ueda S, Watson JW, Nagahisa A (2002) Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret. Pharmacology 66: 144–152

    Article  PubMed  CAS  Google Scholar 

  • Urban LA, Fox AJ NK1 receptor antagonists—are they really without effect in the pain clinic? (2000) Trends Pharmacol Sci 21: 462–464

    Article  PubMed  CAS  Google Scholar 

  • Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 94: 3032–3041

    Article  PubMed  Google Scholar 

  • Vassout A, Schaub M, Gentsch C, Ofner S, Schilling W, Veenstra S (1994) CGRP 49,823, a novel NK1 receptor antagonist: behavioural effects. Neuropeptides 26: 37

    Article  Google Scholar 

  • Vassout A, Veenstra S, Hauser K, Ofner S, Brugger F, Schilling W, Gentsch C (2000) NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats. Regul Pept 96: 7–16

    Article  PubMed  CAS  Google Scholar 

  • Venepalli BR, Aimone LD, Appell KC, Bell MR, Dority JA, Goswami R, Hall PL, Kumar V, Lawrence KB, Logan ME (1992) Synthes is and substance P receptor binding activ ity of androstano [3,2-b)pyrimido[1,2-a)benzimidazoles. J Med Chem 35: 374–378

    Article  PubMed  CAS  Google Scholar 

  • Venkova K, Sutkowski-Markmann DM, Greenwood-Van Meerveld B (2002) Peripheral activity of a new NK1 recepto r ant agonist TAK-637 in the gastrointestinal tract. J Pharmacal Exp Ther 300: 1046–1052

    Article  CAS  Google Scholar 

  • Walpole CS, Brown MC, James IF, Campbell EA, McIntyre P, Docherty R, Ko S, Hedley L, Ewan S, Buchheit KH, Urban LA (1998a) Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br J Pharmacol 124: 83–92

    Article  PubMed  CAS  Google Scholar 

  • Walpole C, Ko SY, Brown M, Beattie D, Campbell E, Dickenson F, Ewan S, Hughes GA, Lemaire M, Lerpiniere J, Patel S, Urban L (1998b) 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-n aphthyl)alanyl-N-benzyl-N-methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain model s. J Med Chem 41: 3159–3173

    Article  PubMed  CAS  Google Scholar 

  • Wang ZY, Tung SR, Strichartz GR, Hakanson R (1994a) Nonspecific actions of the nonpeptide tachykinin receptor antagonists, CP 96,345, RP 67580 and SR 48968, on neurotransmission. Br J Pharmacol 111: 179–184

    Article  PubMed  CAS  Google Scholar 

  • Wang ZY, Tung SR, Strichartz GR, Hakanson R (1994b) Investigation of the specificity of FK 888 as a tachykinin NK1 receptor antagonist. Br J Pharmacol 111: 1342–1346

    Article  PubMed  CAS  Google Scholar 

  • Ward P, Armour DR, Bays DE, Evans B, Giblin GM, Heron N, Hubbard T, Liang K, Middlemiss D, Mordaunt J, Pegg NA, Vinader MV, Watson SP, Heron N, Liang K, Bountra C, Evans DC (1995) Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity. J Med Chem 38: 4985–4992

    Article  PubMed  CAS  Google Scholar 

  • Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, Andrews PL (1995) The ant i-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 115: 84–94

    Article  PubMed  CAS  Google Scholar 

  • Wijkhuisen A, Sagot MA, Frobert Y, Creminon C, Grassi J, Boquet D, Couraud JY (1999) Identification in the NK1 tachykinin receptor of a doma in involved in recognition of neurokinin A and septide but not of substance P. FEBS Lett 447: 155–159

    Article  PubMed  CAS  Google Scholar 

  • Williams, BJ, NR Curtis, AT McKnight, J Maguire, A Foster and R Tridgett, (1988) Development of NK2 selective antagonists. Reg Peptides 22: 189

    Article  Google Scholar 

  • Yashpal K, Radhakrishnan V, Coderre TJ, Henry JL (1993) CP-96,345, but not its stereoisomer, CP-96,344, blocks the nociceptive responses to intrathecally administered substance P and to noxious thermal and chemical stimuli in the rat. Neuroscience 52: 1039–1047

    Article  PubMed  CAS  Google Scholar 

  • Zeng XP, Burcher E (1994) Use of selective antagonists for further characterization of tachykinin NK-2, NK-1 and possible’ septide-selective’ receptors in guinea-pig bronchus. J Pharmacol Exp Ther 270: 1295–1300

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacology Department, Menarini Ricerche, Via Rismondo 12/A, 50131, Florence, Italy

    R. Patacchini & C. A. Maggi

Authors
  1. R. Patacchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. A. Maggi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Experimental and Clinical Pharmacology, Medical University of Graz, Universitätsplatz 4, 8010, Graz, Austria

    Peter Holzer (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Patacchini, R., Maggi, C.A. (2004). Tachykinin NK1 Receptor Antagonists. In: Holzer, P. (eds) Tachykinins. Handbook of Experimental Pharmacology, vol 164. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18891-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18891-6_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62342-4

  • Online ISBN: 978-3-642-18891-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation